

BEST AVAILABLE COPY

SEARCHED			
Class	Sub.	Date	Exmr.
424	131.1	1/15/03	QB
530	387.2		
435	327		
	91.1		
536	23.53 23.4		
536	23.5	2/21/02	SR
530	388.1	3/12/02	SR
	387.2		
	388.8		
	387.3		
435	320.1		
	325		
	70.1		
536	24.3		
424	131.1		
	135.1		
	138.1		
	185.1		
Updated		1/15/03	SR

Declan
 9-26/02
 A210. PA
 9-26/02
 Email 1/2
 2/1/03
 35
 36
 37
 38
 39, 1/17/03
 40
 41
 42
 43
 44
 45
 46

9-26/02
 8/1/03
 8/1/03
 8/1/03
 8/1/03
 8/1/03
 12/17/03

9-26/02
 8/1/03
 8/1/03
 8/1/03

SEARCH NOTES

Discussed 112 seqs w/ Charnier, Then Log + Kader w/ SGB	Date	Exmr.
5/15/99	QB	
Searched Seq ID Nos 1-4 in protein + DNA database + CDR regions of Seq ID Nos 1-4	20 April 02	QB
Searched inventors + keyword at APS, STN, Dialog	14 April 02	QB
08/766350	3/12/02	SR

SEQUENCE SEARCH N-MER: SEQID NOS: 1+3 all commercial DNA databases	2/21/02	SR
60/035345	3/12/02	SR
WEST -11010 -Chatterjee, M.	3/12/02	SR
BIOSCIENCE (STN) -see search notes attached	3/12/02	SR
60/031306 -see note attached	3/13/02	SR
Conferred with Anthony Caputau	3/13/02	SR
SEQUENCE SEARCH SEQ ID NO: 0-4	3/19/02	SR

INTERFERENCE SEARCHED			
Class	Sub.	Date	Exmr.

BEST AVAILABLE COPY

SEARCH NOTES CON'T

updated 11/25/03 SR

SEQ SEARCH 8/31/03
SEQ ID nos.: 1, 2,
3, & 4
- commercial &
interference databases

10/367506 11/25/03 SR

Conferred w/ Brian
Stanton re. utility and
scope of enablement -
advised to drop utility
and maintain scope
of enablement rej.

Conferred w/ Larry
Holmes re. scope of
enablement - advised to
drop enablement rej unless
claims are limited to scFv
Antibodies without a
linker

Conferred w/ Larry
Holmes re. utility of
claimed "immunogenic
compositions" comprising
a polynucleotide - advised
to rej claims under 101 as
lacking utility